Yeji

$MGNX

MACROGENICS INC

Runway:6 mo
NasdaqMarket cap: —CIK 0001125345

Upcoming catalysts

2 surfaced
FDA approvalDate TBD~ low confidence
$MGNXMACROGENICS INC
“following the U.S. Food and Drug Administration (the "FDA") approval of Incyte's Biologics License Application ("BLA") for ZYNYZ™ (retifanlimab-dlwr), the Company will receive a $15 million milestone payment from Incyte.”
FDA approvalDate TBD~ low confidence
$MGNXMACROGENICS INC
margenza
“In 2020, MARGENZA was approved by the U.S. Food and Drug Administration (FDA) in combination with chemotherapy for the treatment of adult patients with HER2-positive metastatic breast cancer who have received two or more prior anti-HER2 regimens, at least one of which was for metastatic disease.”

Drug pipeline

margenza
teplizumab
first indication in the United States (anti-CD3 monoclonal antibody)
MGD010
Healthy Subjects
tebotelimab 1 mg
Advanced Solid Tumors
MGAWN1
West Nile Virus Infection
MGD014
HIV-1-infection
teplizumab or placebo
Type 1 Diabetes Mellitus
Margetuximab
Breast Cancer
vobramitamab duocarmazine
Advanced Solid Tumor
MGD007 + MGA012
Colorectal Cancer Metastatic
RAV12
Pancreatic Cancer
Margetuximab 10 mg/kg
Gastric Cancer
Blood samples for safety
Type 1 Diabetes Mellitus
Flotetuzumab 3 ng/kg/day, 4 days on and 3 days off
AML
Teplizumab Herold Regimen
Type 1 Diabetes Mellitus
MGD007
Colorectal Carcinoma
monoclonal antibody RAV12
Cancer
MGD020
Human Immunodeficiency Virus I Infection
Enoblituzumab
Head and Neck Cancer
enoblituzumab plus ipilimumab
Melanoma
lorigerlimab
Androgen-Independent Prostatic Cancer
Enoblituzumab Schedule 1
Melanoma
vobramitamab duocarmazine 2.0 mg (Arm A)
Castration-Resistant Prostatic Cancer
MGC028
Advanced Solid Tumors
MGA271
Melanoma
obrindatamab
Advanced Solid Tumors
MGD024
Leukemia, Acute Myeloid
flotetuzumab
Acute Myeloid Leukemia
MGD009
Mesothelioma
MGC026 Dose Escalation
Advanced Solid Tumor

Recent & active trials

NCTDrugPhaseStatusPrimary completion
NCT06242470MGC026 Dose EscalationPhase 1Recruiting2028-05-01
NCT06730347lorigerlimabPhase 2Recruiting2027-07-01
NCT05362773MGD024Phase 1Recruiting2026-11-01
NCT06723236MGC028Phase 1Recruiting2026-11-01
NCT05848011lorigerlimabPhase 2Completed2026-02-19
NCT05293496vobramitamab duocarmazinePhase 1Completed2025-06-24
NCT03761017lorigerlimabPhase 1Completed2024-08-29
NCT05551117vobramitamab duocarmazine 2.0 mg (Arm A)Phase 2Terminated2024-07-04
NCT05261191MGD020Phase 1Completed2024-05-29
NCT04082364MargetuximabPhase 3Completed2024-01-15
NCT03729596vobramitamab duocarmazinePhase 2Terminated2023-03-18
NCT03219268tebotelimab 1 mgPhase 1Completed2023-02-08
NCT04634825EnoblituzumabPhase 2Terminated2022-07-29
NCT02152956Flotetuzumab 3 ng/kg/day, 4 days on and 3 days offPhase 2Terminated2022-07-05
NCT01148849MargetuximabPhase 1Completed2022-06-14
NCT03406949obrindatamabPhase 1Completed2022-04-27
NCT03570918MGD014Phase 1Completed2021-09-28
NCT02475213Enoblituzumab Schedule 1Phase 1Completed2021-08-18
NCT02492711MargetuximabPhase 3Completed2021-08-11
NCT02689284Margetuximab 10 mg/kgPhase 2Completed2021-01-01

Recent catalysts

FDA approvalMay 25, 2023· 1108d ago· success
$MGNXMACROGENICS INC
margenza
“openFDA SUPPL (EFFICACY) approval of MARGENZA — application BLA761150”
FDA approvalNov 17, 2022· 1297d ago
$MGNXMACROGENICS INC
teplizumab · first indication in the United States (anti-CD3 monoclonal antibody)
“On November 17, 2022, MacroGenics, Inc. (the ”